UnitedHealth reported Q2 results on Tuesday as EPS is expected to drop 38%, as per Koyfin. The firm faces DOJ scrutiny over Medicare billing, a CEO change, and slowing Optum Health profits. Investors await 2025 guidance reinstatement. Despite a 44% YTD fall, sentiment is 'extremely bullish,' hinting at a potential short squeeze if results beat.